194 related articles for article (PubMed ID: 19212674)
1. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.
Ueda Y; Igishi T; Hashimoto K; Suyama H; Araki K; Sumikawa T; Takeda K; Nakazaki H; Matsunami K; Kodani M; Shigeoka Y; Matsumoto S; Shimizu E
Int J Oncol; 2009 Mar; 34(3):689-96. PubMed ID: 19212674
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
6. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.
Ahn K; O YM; Ji YG; Cho HJ; Lee DH
Yonsei Med J; 2018 Aug; 59(6):727-735. PubMed ID: 29978609
[TBL] [Abstract][Full Text] [Related]
8. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
10. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
[TBL] [Abstract][Full Text] [Related]
11. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
[TBL] [Abstract][Full Text] [Related]
13. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Herynk MH; Beyer AR; Cui Y; Weiss H; Anderson E; Green TP; Fuqua SA
Mol Cancer Ther; 2006 Dec; 5(12):3023-31. PubMed ID: 17172405
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
16. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells.
Chen YL; Law PY; Loh HH
Cancer Res; 2004 Dec; 64(23):8723-30. PubMed ID: 15574783
[TBL] [Abstract][Full Text] [Related]
18. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
Thompson R; Meuth M; Woll P; Zhu Y; Danson S
Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
[TBL] [Abstract][Full Text] [Related]
19. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
20. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Krystal GW; Honsawek S; Kiewlich D; Liang C; Vasile S; Sun L; McMahon G; Lipson KE
Cancer Res; 2001 May; 61(9):3660-8. PubMed ID: 11325836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]